Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Galectin-9

  • Victor L. J. L. Thijssen
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101652

Synonyms

Historical Background

Galectin-9 (gal-9) is a member of the galectin protein family which consists of glycan-binding proteins that share a conserved carbohydrate recognition domain (CRD) and a binding affinity for β-galactoside sugars. Initially, galectins were designated as S-type lectins since it was found that the first discovered galectin, now referred to as galectin-1, depended on thiols (reducing conditions) to be active. Since this was not the case for many other galectins that were discovered later, the designation S-type lectin is now considered outdated. The galectin family name was defined in 1994 and consisted at that time of four members, i.e., galectin-1 to −4 (Barondes et al. 1994; Leffler et al. 2004). Galectin-9 was added to the protein family in 1997 when it was described by three independent groups...

This is a preview of subscription content, log in to check access.

References

  1. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell. 1994;76:597–8.PubMedCrossRefGoogle Scholar
  2. Bi S, Hong PW, Lee B, Baum LG. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance t-cell migration and HIV entry. PNAS. 2011;108:10650–5.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Gieseke F, Kruchen A, Tzaribachev N, Bentzien F, Dominici M, Müller I. Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress t-cell proliferation. Eur J Immunol. 2013;43:2741–9.PubMedCrossRefGoogle Scholar
  4. Heusschen R, Griffioen AW, Thijssen VL. Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta. 2013;1836:177–85.PubMedGoogle Scholar
  5. Heusschen R, Schulkens IA, van Beijnum J, Griffioen AW, Thijssen VL. Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochim Biophys Acta. 2014;1842:284–92.PubMedCrossRefGoogle Scholar
  6. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta. 2002;1572:232–54.PubMedCrossRefGoogle Scholar
  7. Hirashima M, Kashio Y, Nishi N, Yamauchi A, Imaizumi TA, Kageshita T, et al. Galectin-9 in physiological and pathological conditions. Glycoconj J. 2004;19:593–600.CrossRefGoogle Scholar
  8. Horlacher T, Oberli MA, Werz DB, Kröck L, Bufali S, Mishra R, et al. Determination of carbohydrate-binding preferences of human galectins with carbohydrate microarrays. ChemBioChem. 2010;11:1563–73.PubMedCrossRefGoogle Scholar
  9. Leal-Pinto E, Tao W, Rappaport J, Richardson M, Knorr BA, Abramson RG. Molecular cloning and functional reconstitution of a urate transporter/channel. J Biol Chem. 1997;272:617–25.PubMedCrossRefGoogle Scholar
  10. Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F. Introduction to galectins. Glycoconj J. 2004;19:433–40.CrossRefGoogle Scholar
  11. Lipkowitz MS, Leal-Pinto E, Cohen BE, Abramson RG. Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconj J. 2004;19:491–8.CrossRefGoogle Scholar
  12. Matsushita N, Nishi N, Seki M, Matsumoto R, Kuwabara I, Liu FT, et al. Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem. 2000;275:8355–60.PubMedCrossRefGoogle Scholar
  13. Merani S, Chen W, Elahi S. The bitter side of sweet: the role of galectin-9 in immunopathogenesis of viral infections. Rev Med Virol. 2015;25:175–86.PubMedCrossRefGoogle Scholar
  14. Miyanishi N, Nishi N, Abe H, Kashio Y, Shinonaga R, Nakakita S, et al. Carbohydrate-recognition domains of galectin-9 are involved in intermolecular interaction with galectin-9 itself and other members of the galectin family. Glycobiology. 2007;17:423–32.PubMedCrossRefGoogle Scholar
  15. Nagae M, Nishi N, Murata T, Usui T, Nakamura T, Wakatsuki S, et al. Crystal structure of the galectin-9 n-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition. J Biol Chem. 2006;281:35884–93.PubMedCrossRefGoogle Scholar
  16. Nishi N, Itoh A, Shoji H, Miyanaka H, Nakamura T. Galectin-8 and galectin-9 are novel substrates for thrombin. Glycobiology. 2006;16:15C–20C.PubMedCrossRefGoogle Scholar
  17. Orr SL, Le D, Long JM, Sobieszczuk P, Ma B, Tian H, et al. A phenotype survey of 36 mutant mouse strains with gene-targeted defects in glycosyltransferases or glycan-binding proteins. Glycobiology. 2013;23:363–80.PubMedCrossRefGoogle Scholar
  18. Spitzenberger F, Graessler J, Schroeder HE. Molecular and functional characterization of galectin 9 mrna isoforms in porcine and human cells and tissues. Biochimie. 2001;83:851–62.PubMedCrossRefGoogle Scholar
  19. Thijssen VL, Rabinovich GA, Griffioen AW. Vascular galectins: regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev. 2013;24:547–58.PubMedCrossRefGoogle Scholar
  20. Tureci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U. Molecular definition of a novel human galectin which is immunogenic in patients with hodgkin’s disease. J Biol Chem. 1997;272:6416–22.PubMedCrossRefGoogle Scholar
  21. Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem. 1997;272:6078–86.PubMedCrossRefGoogle Scholar
  22. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS. Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J Clin Invest. 1997;99:2452–61.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Wiersma VR, de Bruyn M, Helfrich W, Bremer E. Therapeutic potential of galectin-9 in human disease. Med Res Rev. 2013;33:E102–26.PubMedCrossRefGoogle Scholar
  24. Yang Q, Jiang W, Zhuang C, Geng Z, Hou C, Huang D, et al. MicroRNA-22 downregulation of galectin-9 influences lymphocyte apoptosis and tumor cell proliferation in liver cancer. Oncol Rep. 2015;34:1771–8.PubMedCrossRefGoogle Scholar
  25. Yoshida H, Teraoka M, Nishi N, Nakakita S, Nakamura T, Hirashima M, et al. X-ray structures of human galectin-9 c-terminal domain in complexes with a biantennary oligosaccharide and sialyllactose. J Biol Chem. 2010;285:36969–76.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Departments of Medical Oncology and Radiation OncologyVU University Medical CenterAmsterdamThe Netherlands